BACKGROUND: Sirolimus is a potent immunosuppressive agent, which is associated with dyslipidemia in clinical transplantation. The present study was undertaken to investigate the potential hepatocyte mechanisms by which sirolimus causes dyslipidemia. METHODS: Using both a quantitative assay of intracellular cholesterol and an [3H]-labeled cholesterol efflux assay, we studied the effect of sirolimus on cholesterol accumulation and cholesterol efflux in HepG2 cells in the absence or presence of inflammatory stress induced by interleukin-1beta. The gene and protein expression of molecules involved in cholesterol homeostasis were examined by real-time reverse-transcription polymerase chain reaction and Western blotting. RESULTS: Sirolimus inhibited low-density lipoprotein (LDL) receptor (LDLr)-mediated cholesterol ester accumulation induced by interleukin-1beta in HepG2 cells. This inhibitory effect was mediated by down-regulation of sterol regulatory element-binding proteins (SREBP) cleavage activating protein (SCAP) and SREBP-2 mRNA expression. Using confocal microscopy, we demonstrated that sirolimus reduced translocation of SCAP-SREBP2 complex from endoplasmic reticulum to Golgi for activation, thereby inhibiting LDLr gene transcription. Reduction of LDLr in the liver may result in a delay of LDL-cholesterol clearance from circulation causing an increase of plasma cholesterol concentration. Furthermore, sirolimus increased cholesterol efflux mediated by adenosine triphosphate-binding cassette transporter A1 gene expression by increasing peroxisome proliferator-activated receptor-alpha and liver X receptor-alpha gene and protein expression. Increased cholesterol efflux from HepG2 cells may increase high-density lipoprotein cholesterol level and also contribute to apolipoprotein B lipoprotein formation by enhancing transfer of high-density lipoprotein cholesterol to apolipoprotein B lipoproteins. CONCLUSIONS: This study demonstrates that the increase of LDL cholesterol by sirolimus is partly due to the reduction of LDLr on hepatocytes.
BACKGROUND:Sirolimus is a potent immunosuppressive agent, which is associated with dyslipidemia in clinical transplantation. The present study was undertaken to investigate the potential hepatocyte mechanisms by which sirolimus causes dyslipidemia. METHODS: Using both a quantitative assay of intracellular cholesterol and an [3H]-labeled cholesterol efflux assay, we studied the effect of sirolimus on cholesterol accumulation and cholesterol efflux in HepG2 cells in the absence or presence of inflammatory stress induced by interleukin-1beta. The gene and protein expression of molecules involved in cholesterol homeostasis were examined by real-time reverse-transcription polymerase chain reaction and Western blotting. RESULTS:Sirolimus inhibited low-density lipoprotein (LDL) receptor (LDLr)-mediated cholesterol ester accumulation induced by interleukin-1beta in HepG2 cells. This inhibitory effect was mediated by down-regulation of sterol regulatory element-binding proteins (SREBP) cleavage activating protein (SCAP) and SREBP-2 mRNA expression. Using confocal microscopy, we demonstrated that sirolimus reduced translocation of SCAP-SREBP2 complex from endoplasmic reticulum to Golgi for activation, thereby inhibiting LDLr gene transcription. Reduction of LDLr in the liver may result in a delay of LDL-cholesterol clearance from circulation causing an increase of plasma cholesterol concentration. Furthermore, sirolimus increased cholesterol efflux mediated by adenosine triphosphate-binding cassette transporter A1 gene expression by increasing peroxisome proliferator-activated receptor-alpha and liver X receptor-alpha gene and protein expression. Increased cholesterol efflux from HepG2 cells may increase high-density lipoprotein cholesterol level and also contribute to apolipoprotein B lipoprotein formation by enhancing transfer of high-density lipoprotein cholesterol to apolipoprotein B lipoproteins. CONCLUSIONS: This study demonstrates that the increase of LDL cholesterol by sirolimus is partly due to the reduction of LDLr on hepatocytes.
Authors: Zhen Yu; Rong Wang; Wilson C Fok; Alexander Coles; Adam B Salmon; Viviana I Pérez Journal: J Gerontol A Biol Sci Med Sci Date: 2014-04-22 Impact factor: 6.053
Authors: Mathias J Wawer; David E Jaramillo; Vlado Dančík; Daniel M Fass; Stephen J Haggarty; Alykhan F Shamji; Bridget K Wagner; Stuart L Schreiber; Paul A Clemons Journal: J Biomol Screen Date: 2014-04-07
Authors: Wai-Johnn Sam; Christine E Chamberlain; Su-Jun Lee; Joyce A Goldstein; Douglas A Hale; Roslyn B Mannon; Allan D Kirk; Yuen Yi Hon Journal: Transplantation Date: 2012-11-15 Impact factor: 4.939
Authors: Chuan Wang; Lin Hu; Lei Zhao; Ping Yang; John F Moorhead; Zac Varghese; Yaxi Chen; Xiong Z Ruan Journal: PLoS One Date: 2014-07-21 Impact factor: 3.240
Authors: Ping Yang; Yunfei Zhao; Lei Zhao; Jun Yuan; Yao Chen; Zac Varghese; John F Moorhead; Yaxi Chen; Xiong Z Ruan Journal: Sci Rep Date: 2015-10-09 Impact factor: 4.379
Authors: Wilson C Fok; Alex Bokov; Jonathan Gelfond; Zhen Yu; Yiqiang Zhang; Mark Doderer; Yidong Chen; Martin Javors; William H Wood; Yongqing Zhang; Kevin G Becker; Arlan Richardson; Viviana I Pérez Journal: Aging Cell Date: 2013-12-05 Impact factor: 9.304
Authors: Yuefeng Tang; Martina Wallace; Joan Sanchez-Gurmaches; Wen-Yu Hsiao; Huawei Li; Peter L Lee; Santiago Vernia; Christian M Metallo; David A Guertin Journal: Nat Commun Date: 2016-04-21 Impact factor: 14.919